PharmaResearch Co., Ltd.

A214450

KR7214450009

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
139,600 ^KRW	+8.55%		+17.51%	+27.49%

2023	PharmaResearch Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
2021	PHARMA RESEARCH BIO Co., Ltd. announced that it has received KRW 30 billion in funding from PharmaResearch Co., Ltd.	CI

Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.

February 21, 2020 at 12:58 am EST

From April 1, 2019 to June 30, 2019, the company has repurchased 27,266 shares, representing 0.29% for KRW 1,088.16 million. With this, the company has completed the repurchase of 71,312 shares, representing 0.76% for KRW 2,790.61 million under the buyback announced on February 21, 2019.

Latest news about PharmaResearch Co., Ltd.

PharmaResearch Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
PHARMA RESEARCH BIO Co., Ltd. announced that it has received KRW 30 billion in funding from PharmaResearch Co., Ltd.	21-11-25	CI
PHARMA RESEARCH BIO Co., Ltd. announced that it expects to receive KRW 30 billion in funding from PharmaResearch Co., Ltd.	21-11-23	CI
PharmaResearch Co., Ltd. acquired Medicoson Co., Ltd.	21-11-23	CI
PharmaResearch Co., Ltd. announced that it has received KRW 25 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm	21-10-27	CI
PharmaResearch Co., Ltd. announced that it expects to receive KRW 25 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm	21-10-25	CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.	20-02-21	CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.	20-02-21	CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.	20-02-21	CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.	20-02-21	CI
Pharma Research Products Co., Ltd's Equity Buyback announced on February 21, 2019, has expired with 129,237 shares, representing 1.37% for KRW 4,992.18 million.	20-02-20	CI
Pharma Research Products Co., Ltd's Equity Buyback Plan Extended till February 21, 2020.	19-08-20	CI
Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.	19-05-22	CI
Pharma Research Products Co., Ltd announces an Equity Buyback for KRW 5,000 million worth of its shares.	19-02-21	CI
Pharma Research Products Co., Ltd authorizes a Buyback Plan.	19-02-20	CI
Pharma Research Products Co., Ltd cancelled the acquisition of Cleviel filler business segment from Aestura Corporation.	19-01-10	CI
BIOCND Inc. announced that it has received KRW 10 billion in funding from Pharma Research Products Co., Ltd	18-04-02	CI
Pharma Research Products Co., Ltd completed the acquisition of 42.45% stake in BIOCND Inc. from a group of shareholders.	18-03-27	CI
Ace Susung New Technology Fund 3, Dongyu Investment Co., Ltd and Nau Growth Capital PEF fund managed by Nau IB Capital, Investment Arm completed the acquisition of 3.2% stake in Pharma Research Products Co., Ltd from Jung, Sang-Soo.	18-03-25	CI
Pharma Research Products Co., Ltd announced that it has received KRW 24 billion in funding from Nau IB Capital, Investment Arm, Dongyu Investment Co., Ltd, and another investor	18-03-20	CI
Ace Susung New Technology Fund 3, Dongyu Investment Co., Ltd and Nau Growth Capital PEF fund managed by Nau IB Capital, Investment Arm signed a stock definitive agreement to acquire 3.2% in Pharma Research Products Co., Ltd from Jung, Sang-Soo for KRW 16 billion.	18-03-19	CI
Pharma Research Products Co., Ltd announced that it expects to receive KRW 24 billion in funding from Nau IB Capital, Investment Arm, Dongyu Investment Co., Ltd	18-03-11	CI
Promore Pharma AB Regains Rights for PXL01 Manufacturing from PharmaResearch Products Ltd	18-02-15	CI
BIOCND Inc. announced that it expects to receive KRW 10 billion in funding from Pharma Research Products Co., Ltd	18-01-25	CI
Pharma Research Products Co., Ltd entered into a memorandum of understanding to acquire Cleviel filler business segment from Aestura Corporation for KRW 5.1 billion.	18-01-10	CI

Chart PharmaResearch Co., Ltd.

Duration

Period

More charts

Company Profile

PharmaResearch Co Ltd, formerly Pharma Research Products Co Ltd, is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company produces and sells regenerated products such as pharmaceuticals, medical devices, and cosmetics. In addition, the Company is involved in the venture investment and real estate leasing. The Company mainly provides its products in domestic market.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for PharmaResearch Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

139,600 KRW

Average target price

175,000 KRW

Spread / Average Target

+25.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
PHARMARESEARCH CO., LTD.	+27.49%	1.06B
CSL LIMITED	-3.79%	88.14B
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.51B
BIOGEN INC.	-15.94%	31.67B
UCB	+52.66%	24.62B
BIOMARIN PHARMACEUTICAL INC.	-14.50%	15.65B
INCYTE CORPORATION	-14.38%	12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.97B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.81B

Biopharmaceuticals

PharmaResearch Co., Ltd.

Equities

A214450

KR7214450009

Pharmaceuticals

Tranche Update on Pharma Research Products Co., Ltd's Equity Buyback Plan announced on February 21, 2019.

Latest news about PharmaResearch Co., Ltd.

Chart PharmaResearch Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for PharmaResearch Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Biopharmaceuticals